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Cell-based therapies have evolved out of research laboratories that have extended their reach beyond basic investigation to cell manufacturing for human administration. Manufacturing is not a word that rolls easily off the tongue of most investigators. Manufacturing is defined as any substantial manipulation of cells beyond straightforward collection and cryopreservation. The official designation is a tongue twisting 'more than minimal manipulation.' Although the function of cell manufacturing is already performed by blood collection centers including the fractionation of blood products by centrifugation and filtration, manufacturing of cells for advanced therapies is infrequently available to scientists. Research laboratories have performed cell manufacturing for many reasons, but often because there is no option to delegate the function to a qualified clinical laboratory. The character of research function and activities differs from those of clinical laboratories. Many suppose that imagination and flexibility characterize the research laboratory while documentation and rigidity rule the clinical laboratories.
The absence of a qualified clinical cell-processing laboratory is usually due to numerous issues, but the primary one is cost. The expense of the physical plant is large but is exceeded by the cost of daily maintenance. However, there is an even more challenging resource: regulatory expertise. Few academic centers have had an office for regulatory affairs, and even fewer have had that office devoted to issues of manufacturing as compared to Medicare compliance. The regulatory experience with clinical cell manufacturing resides largely in blood collection and processing centers. Not all academic centers have collection and processing on site, and the activities of transfusion services cover only portion of the regulatory issues.
This economic model of barrier to entry is similar to other industries where the cost of entry is very high, such as the oil industry where the cost of entry to sell a gallon of gasoline is very high, since wells must be drilled, crude oil transported through a pipeline, and the gallon of gasoline must be fractionated in a vast refinery before it can be sold to compete with Exxon or Shell. The barrier before the first patient can be treated is high and long.
'Product regulation may stifle innovation and progress.' 'y it just may be that science is the least of our problems.' 1 With each turn there is a new challenge of regulations, and a proliferation of regulations that must be followed as closely as the last issue of Nature or Science. Voices of frustration are increasingly strident, suggesting that there is overregulation choking off progress in a promising area. The same yardsticks increasingly measure the local laboratory as measure the giant biopharmaceutical company with billions in sales. What reconciliation, if any, is possible? To encourage development of therapies, the extent of requirements is somewhat less at the phase I feasibility studies and increases through the step of phase III studies and approval of drugs. This progression is often referred to as the 'sliding scale' or 'stepwise approach', which is intended to enable development to occur from many sources. There is little question that the 'sliding scale' of regulations between phase I and phase III trials has become more compressed. There is also little question that the regulators are under intense political scrutiny, and the tolerance for any perceived error of regulation is small.
Regulation of drugs and of blood-derived therapies has a long and tortured history. On the one hand, there has been the view that regulation has cutoff promising avenues of therapies, delaying needed and effective therapy, depriving countless persons of potentially life-saving therapy. On the other hand, there have been numerous tragedies whose evaluation and process control might have been avoided, including the deaths of many children when ethylene glycol was used as a carrier for an elixir. Despite the breadth of regulation in the last decade, deaths due to contaminated cellular products persist (two deaths in Minnesota from contaminated banked cartilage). Most recently the caution of gene insertion causing cellular transformation years after the procedure reminds us of the need for caution 2 ( Table 1) . The FDA has long regulated blood banks and transfusion services and their original cellular therapeutic products. 3 A visit by FDA inspectors always raises trepidation and word spreads instantaneously. And indeed the inspection is stressful, but when a blood bank progresses from several citations to not a single '483' there is justifiable pride in the progress of control of the processes in the blood bank. Most college students would admit that there is more discipline when a test or paper is at the end of the line, and the mere knowledge of oversight stimulates additional attention to detail. In addition, the periodic reporting and inspection encourage continued changes and improvement.
Evolution of cell-based regulation
The first somatic cell therapy document was published in the Federal Register over 10 years ago, 4 and in the past year there have been nearly monthly guidance documents published covering variant Creutzfeldt-Jakob disease (for which there is no firm evidence of actual transmission through human blood derived products) to procedures of record keeping, including software validation and electronic record guidances. These guidance documents are always difficult to apply, since they do not have the weight of law, and do not legally bind the FDA to the statements contained therein.
CBER has developed a new Office of Cellular, Tissue and Gene Therapies (OCTGT) to consolidate the activities monitoring biologics into a single office. The OCTGT will be responsible for review of tissues, cellular and tissuebased products, gene therapies, xenotransplantation, and combined cellular therapies. Within this office resides expertise in cell manufacturing, safety analysis, and product characterization that is available to the investigator during the process of IND application.
The Foundation for Accreditation of Cellular Therapy (FACT, formerly FAHCT) has contributed significantly to the comprehensive and reasonable self-regulation of an infant industry. The organization has defined a set of evolving minimal requirements that govern both laboratory and clinical functions associated with cell-based therapies. FACT accreditation is becoming a standard for cell manufacturers perceived to be similar to American Association of Blood Banking accreditation of blood banks ( Table 2) .
Phases of product development
There are several distinct phases of product development in academic cell manufacturing, each presenting specific challenges.
Research laboratory phase
Investigators do not commonly consider the requirements for bringing a therapy to human use. Every material used in the project should be reagent grade or have a clinical grade reagent that may be substituted with high likelihood of comparable results. Animal products should be avoided. Reagents that are developed and produced within the laboratory must be carefully documented with all experimental data, storage conditions in monitored and calibrated equipment, and lot numbers of materials used in production recorded.
Scale-up phase
A demonstration that processes used in small-scale production for animal studies or other preliminary data can be comparably performed in a scale required for clinical application. For example, a change from flasks to bags may introduce variables affecting outcome. 
Current good manufacturing practice
Products manufactured during phase I will need safety data, but there may still be some evolution of the process, the means of characterizing the product, and development of stability data that will be required prior to a phase III trial. A common confusion is the designation 'cGMP facility.' CGMP manufacturing includes validation, control, and documentation of reagents and equipment as well as the environment within which the manufacturing occurs. The facility itself is only a part of the requirements for cGMP. The manufacture of each lot of product must be documented through a batch record, and each lot must be shown to have certain characteristics (a product description), have passed all testing prior to release and be documented in a Certificate of Analysis supplied to the receiving clinical agent.
Clinical trial
Cell-based products developed under IND will be tested in clinical trials under NIH guidelines and the responsibility for adherence to these guidelines resides with the holder of the IND. Ultimately, a product may be approved for human use. The following models may be considered for types of product approvals (Table 3) .
Models for cell-based product development
At least two means of approving cell therapy products can be contemplated. The first is the prevailing view held by the FDA. This current vision is that of the classic commercial model: a company seeks approval for a specific product which is then either manufactured by the company for distribution or is licensed to specific manufacturer who then distributes the product. Many challenges exist for this path. Autologous products introduce the inherent variation of starting materials from diverse individuals, particularly those with diseases that may be rather heterogeneous. The specific characterization of the final product is limited by the short time during which fresh products must be administered after completion of manufacturing. Unless central manufacturing can be accomplished, robust manufacturing methods that can produce a highly uniform product when performed by a single or numerous licensees must be perfected. Alternatively, an allogeneic product that may be applied to any HLA tissue type might avoid the issue of multiple manufacturers, but would need to avoid any HLA restriction short of developing an enormous library of cells for matching a specific patient. The attraction of the commercial model for the regulatory agency is a single agent with which to interact, which then must attest to the adequacy of the manufacturing process or network.
The second is the blood bank model of blood product manufacturing. The Blood Bank model of product manufacturing is the definition by several regulatory bodies of a range of products derived from whole blood. Each blood bank currently must demonstrate its ability to produce consistent products through validation procedures, and then must submit those data for licensure of the product by the FDA. Periodic inspections of the facility assure that the required training, quality programs, equipment monitoring, and error report and management systems are in place. The system assures that blood products are widely available, which are reasonably comparable and produced by a periodically requalified system of blood manufacturers (blood banks).
A similar system for more complex cell manufacturing could be envisioned at a time where technology and knowledge of cell mechanisms allows a smaller number of qualified blood banks to perform more complex cell manufacturing upon demonstration of their ability to consistently manufacture a defined cell product. If product characterization can be conquered by commercial interests, then there is no substantive reason why such definition could not exist for a broadly manufactured cell-based product. Likewise, as manufacturing processes mature, a certain number of basic cell types are likely to develop defined uses.
Challenges for the blood bank system include the development of necessary facilities and staffs, and expertise necessary for cGMP cell manufacturing. Current facilities tend to be extremely expensive, but as processes become more robust (reproducible), closed, and possibly automated, delivery of blood-derived highly defined products that are consistent from laboratory to laboratory becomes feasible. More sophisticated staff training will be required, and the appropriate fees for compensating this type of work must be recoverable. Patent royalties might have a central clearinghouse to be consistent from blood bank to blood bank. Where are we now with cell-based therapies?
Several companies are pursuing defined cell products, with Dendreon Corporation leading with a phase III trial nearly completed. This model is challenging, and the success of a wide network of manufacturing will be key. The alternative is manufacturing of novel cell products under IND, but without a clear path to commercialization (read also, wide application). The apparent dead-end of indefinite INDs is daunting to those pursuing this field.
Our experience with several clinical trials and five INDs has been mixed, as one would expect in a rapidly developing new area. I am impressed that the regulatory groups are gaining experience and often have helpful advice and comments. The sense of mutual learning and cooperation is very strong. At the same time, there is the challenge faced by any governmental agency that highly skilled individuals may be spirited away by industry or other careers, and the consistency over time, as well as the potential vision which experience may enable are critically important but potentially elusive.
Is it regulation that will stop development of novel cellbased therapies? No, enlightened regulation will encourage more rapid development of high quality, highly consistent products. We cannot ignore the political nature of regulation, and intolerance of risk for even apparently low-risk therapies. There exists a 'zero risk' expectation in traditional blood bank products (we spend millions and reduce the donor pool for theoretical risks), which extends to cell therapy products. We must have the vision to identify more than one model to bring cell-based therapies to clinical practice, but we must not skip the critical steps of safety and demonstrated utility. Not regulation, but lack of vision will be our limit, and the regulators and the inventors must share the vision of safety, evolution, and reasonable risk management to bring promising therapies to waiting patients.
